Is ProMetic Life Sciences Inc.’s Fuel For Real? The Stock Just Has Lifted Again

 Is ProMetic Life Sciences Inc.'s Fuel For Real? The Stock Just Has Lifted Again

The stock of ProMetic Life Sciences Inc. (TSE:PLI) is a huge mover today! About 887,381 shares traded hands. ProMetic Life Sciences Inc. (TSE:PLI) has declined 9.62% since March 28, 2016 and is downtrending. It has underperformed by 12.63% the S&P500.
The move comes after 8 months positive chart setup for the $1.68B company. It was reported on Nov, 1 by Barchart.com. We have $3.58 PT which if reached, will make TSE:PLI worth $403.20M more.

ProMetic Life Sciences Inc. (TSE:PLI) Ratings Coverage

Out of 6 analysts covering ProMetic Life Sciences Inc. (TSE:PLI), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $6.70 is the highest target while $3 is the lowest. The $4.94 average target is 70.93% above today’s ($2.89) stock price. ProMetic Life Sciences Inc. has been the topic of 18 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The rating was maintained by Scotia Capital with “Outperform” on Thursday, October 27. The rating was maintained by RBC Capital Markets on Tuesday, December 15 with “Outperform”. The firm has “Outperform” rating given on Tuesday, December 8 by RBC Capital Markets. TD Securities maintained ProMetic Life Sciences Inc. (TSE:PLI) rating on Thursday, October 27. TD Securities has “Speculative Buy” rating and $4.50 price target. Scotia Capital maintained ProMetic Life Sciences Inc. (TSE:PLI) rating on Thursday, August 11. Scotia Capital has “Outperform” rating and $5 price target. Scotia Capital maintained the stock with “Outperform” rating in Monday, August 10 report. RBC Capital Markets maintained ProMetic Life Sciences Inc. (TSE:PLI) on Wednesday, June 15 with “Outperform” rating. RBC Capital Markets maintained ProMetic Life Sciences Inc. (TSE:PLI) on Friday, October 21 with “Outperform” rating. The firm has “Outperform” rating given on Thursday, August 25 by RBC Capital Markets. The stock of ProMetic Life Sciences Inc. (TSE:PLI) earned “Outperform” rating by RBC Capital Markets on Thursday, October 27.

More recent ProMetic Life Sciences Inc. (TSE:PLI) news were published by: Fool.ca which released: “What Is Inflaming ProMetic Life Sciences Inc.’s Latest Increase?” on October 25, 2016. Also Marketwatch.com published the news titled: “Thomvest Asset Management Inc. reports Prometic Life Sciences Inc. share …” on March 11, 2016. Prnewswire.com‘s news article titled: “Telesta Therapeutics Inc. announces final court approval of plan of …” with publication date: October 28, 2016 was also an interesting one.

ProMetic Life Sciences Inc. is a Canada biopharmaceutical company. The company has a market cap of $1.68 billion. The Firm has two divisions: Small Molecule Therapeutics and Protein Technology. It currently has negative earnings. The Firm offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment